Neuroprotection in cerebral ischaemia: Facts and fancies - The need for new approaches

Cerebrovascular Diseases

Volumn 17, Issue SUPPL. 1, 2004, Pages 153-166

  Wahlgren, Nils Gunnar ^a   Ahmed, Niaz ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cerebral ischaemia; Cerebrovascular disorders; Clinical trials; Neuroprotection; Stroke

Indexed keywords

3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; 3,3 BIS(3 FLUOROPHENYL) N METHYLPROPYLAMINE; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; [1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID; [[3,4 DIHYDRO 7 MORPHOLINO 2,3 DIOXO 6 (TRIFLUOROMETHYL) 1(2H) QUINOXALINYL]METHYL]PHOSPHONIC ACID; ALTEPLASE; APTIGANEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHELATING AGENT; CLOMETHIAZOLE; CP 101 606; DARODIPINE; DEXTRORPHAN; DIAZEPAM; DISUFENTON SODIUM; DIZOCILPINE; EBSELEN; ETHYLENEGLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID BIS(2 OCTYLOXYETHYL) ESTER; FIBRINOLYTIC AGENT; FLUNARIZINE; GAVESTINEL; GLUTAMATE RECEPTOR ANTAGONIST; ISRADIPINE; LUB INT 13; MAGNESIUM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NICARDIPINE; NIMODIPINE; POST 010; POST 011; PY 108 068; REMACEMIDE; REPINOTAN; ROVELIZUMAB; SIPATRIGINE; TIRILAZAD; TRAXOPRODIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMBULANCE; BRAIN CELL; BRAIN CIRCULATION; BRAIN INFARCTION; BRAIN ISCHEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL MODEL; FUTUROLOGY; HUMAN; HYPOTENSION; META ANALYSIS; NEUROLOGIC EXAMINATION; NEUROPROTECTION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REPERFUSION INJURY; SEDATION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TECHNIQUE; TREATMENT FAILURE;

ANIMALS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 0346787871     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074808     Document Type: Conference Paper

References (86)

1. Astrup J, Siesjö BK, Symon L: Thresholds in cerebral ischaemia - The ischemic penumbra. Stroke 1981;12:723-725.
2. Olsen TS, Larsen B, Herning M, Skriver EB, Lassen NA: Blood flow and vascular reactivity in collaterally perfused brain tissue: Evidence of an ischemic penumbra in patients with acute stroke. Stroke 1983;14:332-341.
3. Trust Study Group: Randomised, double-blind, placebo-controlled trial of nimodipine in acute stroke. Lancet 1990;336:1205-1209.
4. The American Nimodipine Study Group: Clinical trial of nimodipine in acute ischemic stroke. Stroke 1992;23:3-8.
5. Bogousslavsky J, Regli F, Zumstein V, Kobberling W: Double-blind study of nimodipine in non-severe stroke. Eur Neurol 1990;30:23-26.
6. Wahlgren NG, MacMahon DG, for the IN-WEST Study Group: The Intravenous Nimodipine West European Trial (INWEST) of nimodipine in the treatment of acute ischemic stroke. Cerebrovasc Dis 1994;4:204-210.
7. Sze KH, Sim TC, Wong E, Cheng S, Woo J: Effect of nimodipine on memory after cerebral infarction. Acta Neurol Scand 1998;97:386-392.
8. Paci A, Ottaviano P, Trenta A, Iannone G, De Santis L, Lancia G, Moschini E, Carosi M, Amigoni S, Caresia L: Nimodipine in acute ischemic stroke: A double-blind controlled study. Acta Neurol Scand 1989;80:282-286.
9. Norris JW, LeBrun LH, Anderson BA: The Canwin Study Group: Intravenous nimodipine in acute ischemic stroke. Cerebrovasc Dis 1994;4:194-196.
10. Nag D, Garg RK, Varma M: A randomized double-blind controlled study of nimodipine in acute cerebral ischemic stroke. Indian J Physiol Pharmacol 1998;42:555-558.
11. Martinez-Vila E, Guillen F, Villanueva JA, Matias-Guiu J, Bigorra J, Gil P, Carbonell A, Martinez-Lage JM: Placebo-controlled trial of nimodipine in the treatment of acute ischemic cerebral infarction. Angiology 1990;41(11, pt 2):1010-1016.
12. Kaste M, Fogelholm R, Erila T, Palomaki H, Murros K, Rissanen A, Sarna S: A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke 1994;25:1348-1353.
13. Infeld B, Davis SM, Donnan GA, Yasaka M, Lichtenstein M, Mitchell PJ, Fitt GJ: Nimodipine and perfusion changes after stroke. Stroke 1999;30:1417-1423.
14. Horn J, de Haan RJ, Vermeulen M, Limburg M: Very Early Nimodipine Use in Stroke (VENUS): A randomized, double-blind, placebo-controlled trial. Stroke 2001;32:461-465.
15. Heiss WD, Holthoff V, Pawlik G, Neveling M: Effect of nimodipine on regional cerebral glucose metabolism in patients with acute ischemic stroke as measured by positron emission tomography. J Cereb Blood Flow Metab 1990;10:127-132.
16. Gelmers HJ, Gorter K, de Weerdt CJ, Wiezer HJ: A controlled trial of nimodipine in acute ischemic stroke. N Engl J Med 1988;318:203-207.
17. Gelmers HJ: The effects of nimodipine on the clinical course of patients with acute ischemic stroke. Acta Neurol Scand 1984;69:232-239.
18. Mohr JP, Orgogozo JM, Harrison MJG, Hennerici M, Wahlgren NG, Gelmers JH, Martinez-Vila E, Dycka J, Tettenborn D: Meta-analysis of oral nimodipine trials in acute ischemic stroke. Cerebrovasc Dis 1994;4:197-203.
19. Ahmed N, Nasman P, Wahlgren NG: Effect of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke 2000;31:1250-1255.
20. Rosenbaum D, Zabramski J, Frey J, Yatsu F, Marler J, Spetzler R, Grotta J: Early treatment of ischemic stroke with a calcium antagonist. Stroke 1991;22:437-441.
21. Limburg M, Hijdra A: Flunarizine in acute ischemic stroke: A pilot study. Eur Neurol 1990;30:121-122.
22. Franke CL, Palm R, Dalby M, Schoonderwaldt HC, Hantson L, Eriksson B, Lang-Jenssen L, Smakman J: Flunarizine in stroke treatment (FIST): A double-blind, placebo-controlled trial in Scandinavia and the Netherlands. Acta Neurol Scand 1996;93:56-60.
23. Azcona A, Lataste X: Isradipine in patients with acute ischaemic cerebral infarction: An overview of the ASCLEPIOS programme. Drugs 1990;40(suppl 2):52-57.
24. Oczkowski WJ, Hachinski VC, Bogousslavsky J, Barnett HJ, Carruthers SG: A double-blind, randomized trial of PY108-068 in acute ischemic cerebral infarction. Stroke 1989;20:604-608.
25. Horn J, Limburg M: Calcium antagonists for acute ischaemic stroke. Cochrane Database Syst Rev 2000;2:CD001928.
26. Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, Yasuhara H: Ebselen in acute ischemic stroke: A placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke 1998;29:12-17.
27. Ogawa A, Yoshimoto T, Kikuchi H, Sano K, Saito I, Yamaguchi T, Yasuhara H: Ebselen in acute middle cerebral artery occlusion: A placebo-controlled, double-blind clinical trial. Cerebrovasc Dis 1999;9:112-118.
28. The Internet Stroke Center. Washington University School of Medicine. URL: http://www.strokecenter.org/, 2002.
29. The RANTTAS Investigators: A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke 1996;27:1453-1458.
30. Haley EC Jr: High-dose tirilazad for acute stroke (RANTTAS II). RANTTAS II Investigators. Stroke 1998;29:1256-1257.
31. Bath PM, Iddenden R, Bath FJ, Orgogozo JM: Tirilazad for acute ischaemic stroke. Cochrane Database Syst Rev 2001;4:CD002087.
32. Lees KR, Sharma AK, Barer D, Ford GA, Kostulas V, Cheng YF, Odergren T: Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke 2001;32:675-680.
33. Wahlgren NG, Ranasinha KW, Rosolacci T, Franke CL, van Erven PM, Ashwood T, Claesson L: Clomethiazole acute stroke study (CLASS): Results of a randomized, controlled trial of clomethiazole versus placebo in 1,360 acute stroke patients. Stroke 1999;30:21-28.
34. Wahlgren NG, Matias-Guiu J, Lainez JM, Veloso F, Ranasinha K, Grossman E, Ashwood T: The clomethiazole acute stroke study (CLASS): Safety results in 1,356 patients with hemispheric stroke. J Stroke Cerebrovasc Dis 2000;9:158-165.
35. Wahlgren NG, Bornhov S, Bornhov S, Sharma A, Cederin B, Rosolacci T, Ashwood T, Claesson L, for the CLASS study group: The Clomethiazole Acute Stroke Study (CLASS): Efficacy results in 545 patients classified as total anterior circulation syndrome (TACS). J Stroke Cerebrovasc Dis 1999;8:231-239.
36. Wahlgren NG, Diez-Tejedor E, Teitelbaum J, Arboix A, Leys D, Ashwood T, Grossman E: Results in 95 hemorrhagic stroke patients included in CLASS, a controlled trial of clomethiazole versus placebo in acute stroke patients. Stroke 2000;31:82-85.
37. Lyden P, Shuaib A, Ng K, Levin K, Atkinson RP, Rajput A, Wechsler L, Ashwood T, Claesson L, Odergren T, Salazar-Grueso E: Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): Final results. Stroke 2002;33:122-128.
38. Early GABA-ergic Activation Study in Stroke (EGASIS). Stroke 2002;33:646-655.
39. ARTIST +: AMPA Receptor Antagonist Treatment in Ischemic Stroke Trial, YM872 + Alteplase. Ongoing Clinical Trials Session, 27th Int Stroke Conf, URL: http://stroke.ahajournals.org/, 2002.
40. ARTIST MRI: AMPA Receptor Antagonist Treatment in Ischemic Stroke Trial-MRI. Ongoing Clinical Trials Session, 27th Int Stroke Conf, URL: http://stroke.ahajournals.org/, 2002.
41. Grotta J, Clark W, Coull B, Pettigrew LC, Mackay B, Goldstein LB, Meissner I, Murphy D, LaRue L: Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke: Results of a phase IIa randomized trial. Stroke 1995;26:602-605.
42. Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, Norris J: Selfotel in acute ischemic stroke: Possible neurotoxic effects of an NMDA antagonist. Stroke 2000;31:347-354.
43. Albers GW, Goldstein LB, Hall D, Lesko LM: Aptiganel hydrochloride in acute ischemic stroke: A randomized controlled trial. JAMA 2001;286:2673-2682.
44. Bullock MR, Merchant RE, Carmack CA, Doppenberg E, Shah AK, Wilner KD, Ko G, Williams SA: An open-label study of CP-101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral haemorrhage. Ann NY Acad Sci 1999;890:51-58.
45. Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM: Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Dextrorphan Study Group. Stroke 1995;26:254-258.
46. Muir KW, Lees KR: A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Stroke 1995;26:1183-1188.
47. Mitka M: News about neuroprotectants for the treatment of stroke. JAMA 2002;287:1253-1254.
48. Intravenous Magnesium Efficacy in Stroke Trial (IMAGES). Stroke 2002;33:646-655.
49. Dyker AG, Lees KR: Remacemide hydrochloride: A double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke. Stroke 1999;30:1796-1801.
50. Albers GW, Clark WM, Atkinson RP, Madden K, Data JL, Whitehouse MJ: Dose escalation study of the NMDA glycine-site antagonist licostinel in acute ischemic stroke. Stroke 1999;30:508-513.
51. Sacco RL, DeRosa JT, Haley EC Jr, Levin B, Ordronneau P, Phillips SJ, Rundek T, Snipes RG, Thompson JL: Glycine antagonist in neuroprotection for patients with acute stroke - GAIN Americas: A randomized controlled trial. JAMA 2001;285:1719-1728.
52. Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M, Orgogozo JM, Whitehead J: Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: A randomised controlled trial. GAIN International Investigators. Lancet 2000;355:1949-1954.
53. Lees KR: Cerestat and other NMDA antagonists in ischemic stroke. Neurology 1997;49(suppl 4):S66-S69.
54. Ay H, Ay I, Koroshetz WJ, Finklestein SP: Potential usefulness of basic fibroblast growth factor as a treatment for stroke. Cerebrovasc Dis 1999;9:131-135.
55. Use of anti-ICAM-1 therapy in ischemic stroke: Results of the Enlimomab Acute Stroke Trial. Neurology 2001;57:1428-1434.
56. Grotta J: Lubeluzole treatment of acute ischemic stroke: The US and Canadian Lubeluzole Ischemic Stroke Study Group. Stroke 1997;28:2338-2346.
57. Diener HC, Cortens M, Ford G, Grotta J, Hacke W, Kaste M, Koudstaal PJ, Wessel T: Lubeluzole in acute ischemic stroke treatment: A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke 2000;31:2543-2551.
58. Wayne C, William E, Edward O, Eric R: Cervene in acute ischemic stroke: Results of a double-blind, placebo-controlled, dose-comparison study. J Stroke Cerebrovasc Dis 1999;8:224-230.
59. Clark WM, Raps EC, Tong DC, Kelly RE: Cervene (Nalmefene) in acute ischemic stroke: Final results of a phase III efficacy study. The Cervene Stroke Study Investigators. Stroke 2000;31:1234-1239.
60. Warach S, Pettigrew LC, Dashe JF, Pullicino P, Lefkowitz DM, Sabounjian L, Harnett K, Schwiderski U, Gammans R: Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann Neurol 2000;48:713-722.
61. Clark WM, Warach SJ, Pettigrew LC, Gammans RE, Sabounjian LA: A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology 1997;49:671-678.
62. Clark WM, Williams BJ, Selzer KA, Zweifler RM, Sabounjian LA, Gammans RE: A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 1999;30:2592-2597.
63. Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE: A phase III randomized efficacy trial of 2,000 mg citicoline in acute ischemic stroke patients. Neurology 2001;57:1595-1602.
64. Role of Intravenous Citicoline for Supratentorial Haemorrhage (RICH Study). Ongoing Clinical Trials Session, 27th Int Stroke Conf, URL: http://stroke.ahajournals.org/, 2002.
65. BRAINS (Bayer Randomised Acute Ischaemia Neuroprotectant Study). Stroke 2000;31:2768-2871.
66. Lutsep HL: Repinotan Bayer. Curr Opin Invest Drugs 2002;3:924-927.
67. Muir KW, Hamilton SJ, Lunnon MW, Hobbiger S, Lees KR: Safety and tolerability of 619C89 after acute stroke. Cerebrovasc Dis 1998;8:31-37.
68. Muir KW, Holzapfel L, Lees KR: Phase II clinical trial of sipatrigine (619C89) by continuous infusion in acute stroke. Cerebrovasc Dis 2000;10:431-436.
69. POST: Double-blind, placebo controlled, safety and efficacy trials of intravenous BMS-204352 in patients with acute stroke. Ongoing Clinical Trials Session, 25th Int Stroke Conf, Internet Stroke Center. URL: http://www.stro- kecenter.org/, 2002.
70. De Deyn PP, Reuck JD, Deberdt W, Vlietinck R, Orgogozo JM: Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group. Stroke 1997;28:2347-2352.
71. Major Ongoing Stroke Trials: PASS II (Piracetam Acute Stroke Study II). Stroke 2000;31:2536-2542.
72. Huber M, Kittner B, Hojer C, Fink GR, Neveling M, Heiss WD: Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke. J Cereb Blood Flow Metab 1993;13:526-530.
73. Bassi S, Albizzati MG, Sbacchi M, Frattola L, Massarotti M: Double-blind evaluation of monosialoganglioside (GM1) therapy in stroke. J Neurosci Res 1984;12:493-498.
74. Argentino C, Sacchetti ML, Toni D, Savoini G, D'Arcangelo E, Erminio F, Federico F, Milone FF, Gallai V, Gambi D, et al: GM1 ganglioside therapy in acute ischemic stroke. Italian Acute Stroke Study - Hemodilution + Drug. Stroke 1989;20:1143-1149.
75. Ganglioside GM1 in acute ischemic stroke. The SASS Trial. Stroke 1994;25:1141-1148.
76. Lenzi GL, Grigoletto F, Gent M, Roberts RS, Walker MD, Easton JD, Carolei A, Dorsey FC, Rocca WA, Bruno R, et al: Early treatment of stroke with monosialoganglioside GM-1: Efficacy and safety results of the Early Stroke Trial. Stroke 1994;25:1552-1558.
77. Candelise L, Ciccone A: Gangliosides for acute ischaemic stroke. Cochrane Database Syst Rev 2001;4:CD000094.
78. MacManus JP, Buchan AM: Apoptosis after experimental stroke: Fact or fashion? J Neurotrauma 2000;17:899-914.
79. Rosenblum WI: Apoptosis and stroke pathogenesis. Stroke 1999;30:1154-1155, discussion 1156.
80. Kuschinsky W, Gillardon F: Apoptosis and cerebral ischaemia. Cerebrovasc Dis 2000;10:165-169.
81. Ladurner G: Neuroprotection in acute ischaemic stroke (abstracts of the International Stroke Conference 2001). Stroke 2001;32:323-c.
82. Lyden P, Jacoby M, Schim J, Albers G, Mazzeo P, Ashwood T, Nordlund A, Odergren T: The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): Final results. Neurology 2001;57:1199-1205.
83. Grotta J: Combination Therapy Stroke Trial: rt-PA ± Lubeluzole. Stroke 2000;31:278.
84. Grotta J: Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke 2002;33:306-307.
85. Lees KR: Neuroprotection is unlikely to be effective in humans using current trial designs: An opposing view. Stroke 2002;33:308-309.
86. Davis SM, Donnan GA: Neuroprotection: Establishing proof of concept in human stroke. Stroke 2002;33:309-310.